Lorlatinib (Lorviqua, Pfizer) is indicated for the 'treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) previously not treated with an ALK inhibitor or whose disease has progressed after prior treatment with an ALK inhibitor'.
The dosage schedule is available in the summary of product characteristics for lorlatinib.
The list price of 30 lorlatinib 100‑mg tablets and 90 lorlatinib 25‑mg tablets is £5,283 (excluding VAT; BNF online accessed July 2025).
The company has a commercial arrangement. This makes lorlatinib available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on Pfizer's website (PDF only).